# A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

> **NCT01200394** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 256 (actual)

## Conditions studied

- Diabetic Nephropathies

## Interventions

- **DRUG:** PF-00489791
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01200394
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-07
- **Final completion:** 2013-08
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2019-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01200394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01200394, "A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01200394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*